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ANGPTL2 activity in cardiac pathologies
accelerates heart failure by perturbing cardiac
function and energy metabolism
Zhe Tian1,2,*, Keishi Miyata1,3,*, Tsuyoshi Kadomatsu1,*, Haruki Horiguchi1,4, Hiroyuki Fukushima5,
Shugo Tohyama6, Yoshihiro Ujihara7, Takahiro Okumura8, Satoshi Yamaguchi9, Jiabin Zhao1, Motoyoshi Endo1,
Jun Morinaga1, Michio Sato1, Taichi Sugizaki1, Shunshun Zhu1, Kazutoyo Terada1, Hisashi Sakaguchi2,
Yoshihiro Komohara10, Motohiro Takeya10, Naoki Takeda4, Kimi Araki4, Ichiro Manabe11, Keiichi Fukuda6,
Kinya Otsu12, Jun Wada9, Toyoaki Murohara8, Satoshi Mohri7, Jun K. Yamashita5, Motoaki Sano6 & Yuichi Oike1
A cardioprotective response that alters ventricular contractility or promotes cardiomyocyte
enlargement occurs with increased workload in conditions such as hypertension. When that
response is excessive, pathological cardiac remodelling occurs, which can progress to heart
failure, a leading cause of death worldwide. Mechanisms underlying this response are not
fully understood. Here, we report that expression of angiopoietin-like protein 2 (ANGPTL2)
increases in pathologically-remodeled hearts of mice and humans, while decreased cardiac
ANGPTL2 expression occurs in physiological cardiac remodelling induced by endurance
training in mice. Mice overexpressing ANGPTL2 in heart show cardiac dysfunction caused by
both inactivation of AKT and sarco(endo)plasmic reticulum Ca2þ -ATPase (SERCA)2a
signalling and decreased myocardial energy metabolism. Conversely, Angptl2 knockout mice
exhibit increased left ventricular contractility and upregulated AKT-SERCA2a signalling and
energy metabolism. Finally, ANGPTL2-knockdown in mice subjected to pressure overload
ameliorates cardiac dysfunction. Overall, these studies suggest that therapeutic ANGPTL2
suppression could antagonize development of heart failure.
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A
cardioprotective response to increase left ventricular
contractile ability and improve myocardial metabolism
occurs with increased workload in cardiac conditions such
as hypertension. When this response is excessive, pathological
cardiac remodelling occurs, a condition often progressing to
heart failure (HF), a leading cause of death that affects more
than 23 million people worldwide1. HF is a cardiac dysfunction
marked by perturbations in adequate oxygen supply required to
maintain proper heart contractility and energy production2.
Decreased cardiac contractility seen in HF is marked by reduced
ejection fraction (HFrEF). By contrast, in HF associated with
preserved ejection fraction (HFpEF), contractile function
appears normal despite the presence of symptoms and the
condition is thought to be caused by abnormal diastolic function3.
Both contraction and relaxation are major energy-consuming
processes4,5, suggesting that failure of myocardial energy
metabolism underlies both HFrEF and HFpEF.
Cardiac hypertrophy, deﬁned as increased heart mass caused
due to cardiomyocyte enlargement, is also an adaptive response
that maintains cardiac function in response to increased
workload6–8. Pathological stimuli, such as hypertension,
promote the transition from hypertrophy to HF, the latter
condition associated with cardiac ﬁbrosis and re-expression of a
fetal cardiac gene programme9. By contrast, exercise induces
physiological hypertrophy characterized by preserved myocardial
structure and energy metabolism, protecting the heart from
HF10–12. Mechanistic differences between physiological and
pathological hypertrophy remain unclear.
The signalling factor angiopoietin-like protein 2 (ANGPTL2),
one of eight ANGPTL proteins13, functions in maintenance
of tissue homeostasis by inducing inﬂammation and
angiogenesis14,15. In some contexts, ANGPTL2 overexpression
promotes irreversible pathological tissue remodelling and
development or progression of obesity-associated metabolic
diseases, type 2 diabetes, atherosclerotic vascular diseases and
some cancers16–23. In these conditions, ANGPTL2 expression
increases in inﬁltrating immune cells or resident cells, such as
adipocytes, vascular endothelial cells and tumour cells. Enhanced
ANGPTL2 autocrine or paracrine signalling accelerates disease
development and progression. Several studies report ANGPTL2
expression in heart13,17, although its function in those tissues has
not been clariﬁed.
Here, we report that cardiac ANGPTL2 expression increases in
pathologically stressed hearts in mice and humans. Mice over-
expressing ANGPTL2 in heart showed cardiac dysfunction
accompanied by inactivation of AKT and sarco(endo)plasmic
reticulum Ca2þ -ATPase (SERCA)2a signalling and by decreased
myocardial energy metabolism. In contrast, Angptl2 knockout
(KO) mice showed increased left ventricular contractile capacity
via increases in AKT-SERCA2a signalling, myocardial
energy metabolism and ATP production, all of which protected
mice from HF in a pressure overload model. Furthermore,
Angptl2 KO phenotypes resembled exercise-induced hypertrophy.
Accordingly, cardiac ANGPTL2 expression signiﬁcantly
decreased in physiological cardiac remodelling induced by
endurance training in mice. Importantly, in a mouse pressure
overload model, suppression of cardiac ANGPTL2 induction
blocked HF development and was accompanied by increased
AKT-SERCA2a signalling and improved cardiac energy
metabolism. ANGPTL2-knockdown (KD) human-induced plur-
ipotent stem cell (iPS)-derived cardiomyocytes showed induction
of AKT-SERCA2a signalling and proper myocardial energy
metabolism compared with control iPS-derived cardiomyocytes.
Together, these results suggest that increased ANGPTL2 activity
accelerates cardiac dysfunction and that therapeutic ANGPTL2
suppression could antagonize this condition.
Results
Elevated ANGPTL2 expression in stressed cardiomyocytes. To
assess ANGPTL2 function in heart, we assessed ANGPTL2
protein levels in stressed heart tissues induced by pressure
overload in wild-type (WT) mice using transverse aorta
constriction (TAC). TAC animals showed higher ANGPTL2
protein levels than did sham-operated controls (Fig. 1a). TAC
mice developed pathological cardiac remodelling with left
ventricular dilatation, decreased fractional shortening and
increased expression of the HF markers ANP, BNP and Myh7
and cardiac ﬁbrosis markers CTGF, Col1 and Col3a1, and
developed HFrEF caused by systolic dysfunction with left
ventricular dilatation (Supplementary Fig. 1a,b).
Moreover, using an alternate model of HF based on
Angiotensin II (Ang II) administration, we observed that
ANGPTL2 protein levels in stressed heart tissues resulting from
Ang II infusion signiﬁcantly increased relative to vehicle-infusion
controls (Fig. 1b). In this model, mice showed no left ventricular
dilatation and preserved fractional shortening but exhibited a
reduced the peak early distolic ﬁling velocity (E-wave) per the
peak atrial ﬁling velocity (A-wave) (E/A) ratio and increased
expression of HF and cardiac ﬁbrosis markers (Supplementary
Fig. 1c–e), conﬁrming that mice in this model develop HFpEF, as
reported previously24,25.
To determine what cells express ANGPTL2 in heart, we
separated cardiomyocytes from non-cardiomyocytes in transgenic
(Tg) mice expressing enhanced green ﬂuorescent protein (EGFP)
under control of the cardiomyocyte-speciﬁc promoter aMHC
(aMHC-EGFP Tg mice). Immunoblotting revealed more
abundant ANGPTL2 expression in GFP-positive cardiomyocytes
than in GFP-negative cells (Fig. 1c; Supplementary Fig. 1f,g).
RT-PCR analysis also revealed increased Angptl2 expression in
GFP-positive cardiomyocytes in cells from both TAC and
Ang II-induced stressed hearts (Fig. 1d,e), suggesting that
ANGPTL2 expression increases in stressed cardiomyocytes
during pathological cardiac remodelling.
NFAT increases Angptl2 expression in cardiomyocytes. To
identify factors governing ANGPTL2 expression in stressed heart
tissues, we stimulated cultured neonatal rat cardiomyocytes
(NRCMs) with Ang II or isoproterenol (Iso), drugs known
to induce pathological remodelling. Treatment with either
signiﬁcantly increased Angptl2 mRNA levels in NRCMs (Fig. 1f).
Both Ang II and Iso reportedly promote nuclear translocation of
NFAT26,27, a key transcription factor underlying development of
pathological cardiac remodelling28, and we previously reported
that the presence of a complex of NFAT, ATF2 and c-jun is
associated with increased Angptl2 transcription in lung and
breast tumour cells22. Immunocytochemical analysis conﬁrmed
that NFATC1 and NFATC4, both expressed in cardiomyocytes29,
undergo nuclear translocation after Ang II treatment, an activity
inhibited by cyclosporine A (CsA), which inhibits the calcium-
dependent protein phosphatase calcineurin (Supplementary
Fig. 2a). CsA treatment also blocked Ang II- or Iso-dependent
Angptl2 upregulation in NRCMs (Fig. 1f). Ang II-stimulated
increases in ANGPTL2 protein levels in NRCMs were blocked by
CsA treatment (Fig. 1g). Moreover, treatment of NRCMs with
xestospongin C (Xes C), an IP3 receptor antagonist that blocks
elevation of cytosolic calcium concentration, inhibited Ang II-
induced Angptl2 expression (Fig. 1h). In addition, overexpression
of constitutively active NFAT (CA-NFAT) increased Angptl2
mRNA levels in NRCMs (Fig. 1i). Finally, immunocytochemical
analysis revealed that NFATC4 underwent nuclear translocation
in stressed heart tissue following either TAC or Ang II infusion
(Supplementary Fig. 2b), suggesting that calcineurin-NFAT
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signalling increases ANGPTL2 expression in stressed heart in
both contexts.
Elevated ANGPTL2 impairs cardiomyocyte contractility. We
next asked whether increased levels of ANGPTL2 proteins alter
cardiac physiology. To do so, we generated four independent Tg
mouse lines overexpressing ANGPTL2 in cardiomyocytes under
control of the aMHC promoter (aMHC-Angptl2 Tg mice)
(Supplementary Fig. 3a,b). All mice appeared normal at birth and
showed no gross perturbations in cardiac development. Three
lines (#1-9, #2-3 and #2-14) showed increased ANGPTL2
expression in heart comparable to that seen in TAC-induced
pathological remodelling (Fig. 1a; Supplementary Fig. 3b) and
two (#1-9 and #2-3) were chosen for further analysis. Compared
with WT littermates, 6-week-old aMHC-Angptl2 Tg mice of both
lines showed decreased cardiac systolic contractile ability without
histological cardiomyocyte enlargement. Twelve-week-old Tg
mice exhibited cardiac systolic dysfunction and showed histolo-
gical cardiomyocyte enlargement and increased expression of
ANP and Myh7 and CTGF and Col1 compared with WT
littermates of both lines (Fig. 2a–c; Supplementary Fig. 3c,d for
representative results in #1-9). Although cardiomyocyte
enlargement was seen in 12-week-old Tg mice of both lines,
left ventricular (LV) wall thickness as evaluated by ultrasonic
echocardiography was not present (Fig. 2a,b), suggesting that
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Figure 1 | ANGPTL2 expression is increased in stressed cardiomyocytes. (a–c) Representative western blot and quantitation of ANGPTL2 protein in
hearts from WTmice 6 weeks after TAC or sham surgery (n¼ 5 per group) (a) and 2 weeks after Angiotensin II (Ang II) or vehicle treatment
(n¼8 per group) (b). Analysis of ANGPTL2 and GFP protein from GFPþ cardiomyocytes and GFP non-cardiomyocytes from Myh6-EGFP Tg mice (n¼ 3
per group) (c). Hsc70 served as a loading control. Normalized values from controls (a,b) or GFPþ cardiomyocytes (c) were set to 1. (d,e) Quantitative RT-
PCR analysis of Angptl2 expression in GFPþ and GFP– cells 6 weeks after TAC or sham surgery (d) and 2 weeks after Ang II or vehicle treatment (e) (n¼ 3
per group). Values for respective controls were set to 1. (f,g) Relative ANGPTL2 transcript (f) and protein (g) levels in NRCMs assessed 6 or 12 h after Ang
II (left in f,g) or Iso (right in f) treatment, with or without cyclosporine A (CsA) treatment. Values before treatment were set to 1. n¼4–8 per group.
(h) Relative ANGPTL2 transcript levels in NRCMs 8 h after Ang II treatment, with or without xestospongin C (Xes C) treatment. Values from control
NRCMs were set to 1. n¼8 per group. (i) Relative Angptl2 transcript levels in NRCMs overexpressing constitutively active NFAT (CA-NFAT). Values from
control NRCMs were set to 1. n¼ 3 per group. Data are means±s.e.m. Statistical signiﬁcance was determined by Student’s t test (a–e and i) or one-way
ANOVA (f–h). *Po0.05, **Po0.01, wPo0.001 between groups.
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increased ANGPTL2 levels in heart primarily attenuate cardiac
contractile capacity.
Cardiac contractile dysfunction is associated with abnormal
Ca2þ handling in cardiomyocytes30. To assess excitation
contraction (E-C) coupling of cardiomyocytes overexpressing
ANGPTL2, we analyzed contractility and Ca2þ transients
induced by electrical stimulation at 1 Hz in single cells isolated
from aMHC-Angptl2 Tg (#1-9) and WT control mice.
Fractional shortening was markedly reduced in cardiomyocytes
overexpressing ANGPTL2 relative to controls (Fig. 2d). In
addition, in ANGPTL2-overexpressing cardiomyocytes, the
magnitude of electrically evoked Ca2þ transients was 68%
that of WT values (Fig. 2e,f). The time to peak [Ca2þ ]i
and the time constant of Ca2þ transient decay were prolonged
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relative to controls in ANGPTL2-overexpressing cardiomyocytes
(Fig. 2e,g,h). Moreover, sarcoplasmic reticulum (SR) Ca2þ
content in cardiomyocytes from aMHC-Angptl2 Tg mice
was signiﬁcantly lower relative to that in WT littermates
(Fig. 2i; Supplementary Fig. 3e). These ﬁndings indicate that
increased ANGPTL2 expression impairs cardiomyocyte
contractility and Ca2þ cycling.
Cardiac function requires constant intracellular ATP
production31,32. Because aMHC-Angptl2 Tg mice exhibit
attenuated cardiac contractility, we compared expression of
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genes regulating myocardial energy metabolism in aMHC-
Angptl2 Tg and WT controls. Expression of energy-related
genes, including PGC-1a and PPARa (both of which regulate
b-oxidation and mitochondrial biogenesis)33,34, as well as genes
that function in intracellular ATP production was signiﬁcantly
decreased in aMHC-Angptl2 Tg (Fig. 2j,k), suggesting that
increased ANGPTL2 expression in cardiomyocytes is associated
with altered mitochondrial energy metabolism.
Elevated cardiac ANGPTL2 predisposes to cardiac dysfunction.
To assess a potential function for high ANGPTL2 levels seen in
pathologically-remodeled hearts, we performed TAC in
aMHC-Angptl2 Tg mice and asked whether animals were
predisposed to cardiac dysfunction. Three weeks after TAC,
WT mice developed adaptive cardiac hypertrophy without left
ventricular dilatation (Fig. 3a–c). By contrast, aMHC-Angptl2
Tg mice developed marked left ventricular dilatation with an
advanced decrease in fractional shortening, resulting in HFrEF
development accompanied by lung congestion (Fig. 3a–c;
Supplementary Fig. 3f). Expression levels of HF and ﬁbrosis
markers, as estimated by RT-PCR analysis of heart tissue,
signiﬁcantly increased in aMHC-Angptl2 Tg relative to control
TAC mice (Fig. 3e). Fibrosis area, as estimated by histological
analysis of heart tissue, signiﬁcantly increased in aMHC-Angptl2
Tg relative to control TAC mice (Fig. 3a,d). After TAC,
intracellular ATP production signiﬁcantly decreased in
aMHC-Angptl2 Tg relative to WT TAC mice (Fig. 3f).
By 8 weeks after TAC, about 70% of aMHC-Angptl2 Tg mice had
died, while only 10% of control mice had died (Fig. 3g).
Moreover, in a model of HFpEF based on Ang II administration,
ultrasonic echocardiography revealed that WT mice
showed preserved cardiac systolic function, as estimated by
fractional shortening analysis, while aMHC-Angptl2 Tg mice
developed HFrEF with severe cardiac systolic dysfunction
caused by decreased fractional shortening (Fig. 3h).
In addition, heart weight markedly increased relative to
control WT mice (Fig. 3i), as did expression of markers of HF and
ﬁbrosis in aMHC-Angptl2 Tg following Ang II administration
(Fig. 3j).
We next asked whether excess cardiac ANGPTL2 expression
could antagonize exercise-induced cardioprotection by
comparing endurance capacity following running exercise in
aMHC-Angptl2 Tg and WT littermates. In the course of testing,
we eliminated 5 of 8 aMHC-Angptl2 Tg mice chosen for analysis
as they were unable to sustain running due to exhaustion,
whereas all WT littermates could perform the exercise
(Supplementary Fig. 3g). These ﬁndings strongly suggest that
cardiac remodelling in aMHC-Angptl2 Tg mice is pathological
rather than physiological.
Endurance exercise training suppresses ANGPTL2 expression.
We conﬁrmed that exercise-trained WT mice exhibit
cardiomyocyte enlargement (Supplementary Fig. 4a) and
increases in cardiac systolic contractile ability, while their
expression of heart and ﬁbrosis markers decreased relative to
sedentary controls (Supplementary Fig. 4b,c). Moreover, cardiac
expression of PGC-1a and PPARa in exercise-trained mice
showed a relative increase (Supplementary Fig. 4d), ﬁndings in
agreement with the idea that cardiac hypertrophy in this context
is not pathological.
Interestingly, compared with outcomes seen in sedentary
control mice, ANGPTL2 protein levels markedly decreased in
hearts of mice undergoing acute treadmill training, and these
decreases persisted in hearts of mice undergoing chronic training
(Fig. 4a). To assess underlying mechanisms, we asked whether
microRNAs might regulate ANGPTL2 expression in heart.
Analysis of the microRNA.org database identiﬁed ﬁve candidates,
including miR-135a, miR-204, miR-211, miR-221 and miR-222,
predicted to bind to the Angptl2 mRNA 30UTR. We observed that
miR-221 or miR-222 overexpression in NRCMs signiﬁcantly
attenuated activity of a luciferase reporter fused to the
Angptl2-30UTR (Fig. 4b), an activity blocked by deletion of
miR-221/222 binding sequences from the UTR (Fig. 4c).
To determine whether miR-221/222 suppresses ANGPTL2
expression in vivo, we generated cardiomyocyte-speciﬁc miR-221/
222 KO male mice by crossing miR-221/222Flox/y mice with aMHC-
Cre mice. We conﬁrmed that miR-221 and miR-222 expression
levels in heart of these were signiﬁcantly decreased relative to control
miR-221/222Flox/y mice (Supplementary Fig. 5a). When we subjected
miR-221/222 KO and miR-221/222Flox/y control mice to chronic
exercise training, we found that ANGPTL2 protein levels in heart
tissues of exercised miR-221/222Flox/y control mice were signiﬁcantly
lower than that seen in sedentary miR-221/222Flox/y controls
(Fig. 4d). In contrast, an exercise-induced decrease in cardiac
ANGPTL2 protein levels did not occur in hearts of exercised
miR-221/222 KO mice (Fig. 4d).
Angptl2 KO mice resist HF development. We next assessed
Angptl2 KO mice to determine whether cardiac ANGPTL2
deﬁciency alters pathological remodelling17. Angptl2 KO mice are
grossly normal at birth and show no overt cardiac phenotypes.
Compared with WT controls, 6-week-old Angptl2 KO mice
showed increased cardiac systolic contractile ability but no
cardiomyocyte enlargement, and 12-week-old Angptl2 KO mice
showed increased cardiac systolic contractile ability and exhibited
cardiomyocyte enlargement with LV wall thickness (Fig. 5a–d).
However, expression of HF markers in hearts of 12-week-old
Angptl2 KO mice was relatively decreased, while ﬁbrosis markers
remained unchanged (Fig. 5e). Expression of energy-related genes
in hearts of 12-week-old Angptl2 KO mice signiﬁcantly increased,
Figure 3 | ANGPTL2-overexpressing mice are predisposed to HF. (a) Shown are representative M-mode echocardiography recordings (top row),
HE-stained sections of heart mid-portion (second row, Scale bar, 1mm), gross appearance of whole heart (third row) and lung (fourth row) and sections of
Masson’s Trichrome-stained heart tissue (bottom row, Scale bar, 100mm) from aMHC-Angptl2 Tg and WT littermate mice 3 weeks after TAC or sham
surgery. Ruler tick marks represent 1mm. (b–e) Comparison of heart tissue from aMHC-Angptl2 Tg and WT littermate mice 3 weeks after TAC or sham
surgery. (b) FS (%), reduction percentage of FS (%), and LVID;d. (c) Heart weight per body weight (HW/BW) ratio and lung weight per body weight
(LW/BW) ratio. (d) Percentage of ﬁbrosis area. (e) Relative expression of genes associated with HF and cardiac ﬁbrosis. WTvalues were set to 1. n¼ 6–10
per group. (f) ATP levels in hearts of aMHC-Angptl2 Tg and WTmice 3 weeks after TAC or sham surgery. n¼6–11 per group. (g) Kaplan–Meier
curve analysis following TAC surgery in aMHC-Angptl2 Tg (n¼ 13) compared with WT (n¼ 28) mice. Po0.001 between genotypes by log-rank test.
(h) Representative M-mode echocardiography recordings (left), %FS (middle) and percent reduction of FS (right) in aMHC-Angptl2 Tg and WT littermate
mice 2 weeks after Ang II or vehicle treatment (n¼4–5 per group). (i) HW/BW ratio from aMHC-Angptl2 Tg and littermate mice 2 weeks after Ang II or
vehicle treatment (n¼4–5 per group). (j) Relative expression of markers of HF and cardiac ﬁbrosis in heart of aMHC-Angptl2 Tg and WT littermate mice
2 weeks after Ang II or vehicle treatment (n¼4–5 per group). Levels seen in vehicle-treated WTmice were set to 1. Data are means±s.e.m. Statistical
signiﬁcance was determined by Student’s t test (c–f,i,j, percent reduction of FS in b and h, and LVID;d in b) or two-way ANOVA (%FS in b and h). *Po0.05,
**Po0.01, wPo0.001 between genotypes or groups.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13016
6 NATURE COMMUNICATIONS | 7:13016 | DOI: 10.1038/ncomms13016 | www.nature.com/naturecommunications
as did intracellular ATP production in both 6- and 12-week-old
KO mice relative to WT littermates (Fig. 5f,g). PGC-1a and
PPARa expression and that of CD36 (a receptor for fatty acids)
also signiﬁcantly increased in 6-week-old Angptl2 KO relative to
WT control mice (Supplementary Fig. 6a). Consistently, PPARa
and PGC-1a expression and intracellular ATP production
signiﬁcantly increased in Angptl2-KD primary NRCMs, while
PPARa expression (but not PGC-1a) and ATP production
signiﬁcantly decreased in NRCMs transduced with adenovirus-
expressing ANGPTL2 (Supplementary Fig. 7a–d). These
ﬁndings indicate that ANGPTL2 suppression in cardiomyocytes
increases expression of genes promoting b-fatty acid oxidation,
mitochondrial biogenesis and intracellular ATP production.
To further assess Angptl2 function we evaluated effects of
TAC on Angptl2 KO mice. At 6 weeks after TAC, WT littermate
controls developed left ventricular dilatation with reduced
fractional shortening, leading to HFrEF development (Fig. 5h,i).
Angptl2 KO mice also showed decreased fractional shortening,
but to a lesser degree, and retained adaptive cardiac hypertrophy
without ventricular dilatation (Fig. 5h,i; Supplementary Fig. 6b).
HF markers expression was signiﬁcantly lower in Angptl2 KO
compared with control mice (Fig. 5j), whereas ﬁbrosis markers
were comparably expressed (Supplementary Fig. 6c). Intracellular
ATP production was maintained at a higher level after TAC in
Angptl2 KO relative to control mice, in agreement with its
function in preserving cardiac contractility (Fig. 5k).
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Figure 4 | Endurance exercise training decreases ANGPTL2 expression in heart. (a) Representative immunoblotting and quantitation of ANGPTL2
protein from hearts of sedentary versus acute or chronic endurance-trained WTmice. Hsc70 served as a loading control. Values from sedentary WTmice
are set to 1. n¼ 6–8 per group. (b) Predicted miR-221, miR-222, miR-211, miR-204 and miR-135a binding sites in the mouse Angptl2-30UTR in the
FLuc-Angptl2-30UTR reporter construct. Relative luciferase activity in NRCMs harbouring the reporter and transfected with control pcDNA3.1 vector or
miR-221, miR-222, miR-211, miR-204 or miR-135a expression vectors. (c) Schematic showing reporter constructs with or without mutated miR-221/222
binding sites (upper). (Lower) relative luciferase activity in NRCMs harbouring WTor mutant reporter constructs and transfected with control or miR-221
or miR-222 expression vectors. Values from NRCMs transfected with vector alone were set to 1. n¼ 10–12 per group. (d) Representative western blot (left)
and quantiﬁcation (right) of ANGPTL2 in heart of control and miR-221/222 KO mice after chronic exercise training (n¼ 7–8 per group). Hsc70 served as
loading control. Levels in control mice in the sedentary group were set at 1. Data are means±s.e.m. Statistical signiﬁcance was determined by Student’s
t test (d) or one-way ANOVA (a–c). *Po0.05, **Po0.01, wPo0.001 between groups.
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We next asked whether cardiac phenotypes observed
in Angptl2 KO mice were attributable to deﬁciency of
cardiomyocyte-derived ANGPTL2. To do so, we generated
cardiomyocyte-speciﬁc Angptl2 conditional KO mice
(Angptl2Flox/Flox;aMHC-Cre), and conﬁrmed that ANGPTL2
protein levels in whole heart tissue of Angptl2Flox/Flox;
aMHC-Cre mice decreased signiﬁcantly relative to controls
(Supplementary Fig. 8a–e). Six weeks after TAC, Angptl2Flox/Flox
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Figure 5 | Angptl2 KO mice show resistance to HF development. (a) Shown are representative M-mode echocardiography recordings (upper),
WGA-stained left ventricle sections (middle, Scale bar, 50mm) and DAPI staining (lower, Scale bar, 200mm). (b–d) Quantitation of LVPW;d, LVID;d, and
%FS in 6-, 12- and 20-week-old Angptl2 KO and WT littermate mice (b) and cardiomyocyte cell size (c) and nuclear density (d) in tissues from 6- and
12-week-old Angptl2 KO and WT littermate mice. (e) Relative expression of genes associated with HF and ﬁbrosis in hearts of 12-week-old Angptl2 KO
compared with WT littermates. WT values were set to 1. (f) Relative expression of genes associated with energy metabolism (left), b-fatty acid oxidation
(middle) and mitochondrial biogenesis (right) in hearts of 15-week-old Angptl2 KO and WTmice. WTvalues were set to 1. (g) Quantitation of ATP levels in
hearts of 6- and 12-week-old mice of indicated genotypes. (h) Representative M-mode echocardiography recordings (upper) and HE-stained sections of
the heart mid-portion (lower, Scale bar, 1mm) 6 weeks after TAC or sham surgery. (i) Comparisons of indicated heart parameters between Angptl2 KO and
WT littermate mice 6 weeks after TAC or sham surgery. (j) Relative expression of genes associated with HF in heart 6 weeks after TAC or sham surgery.
n¼ 5–6 (a–f and h–j) and 9 (g) per group. (k) ATP levels in hearts of Angptl2 KO and WT littermate mice 3 weeks after TAC or sham surgery. n¼ 7–9 per
group. Data are means±s.e.m. Statistical signiﬁcance was determined by Student’s t test (a–g,j,k, and percent reduction of FS and LVID;d in i) or two-way
ANOVA (%FS in i). *Po0.05, **Po0.01, wPo0.001 between genotypes or groups.
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control mice showed clear evidence of decreased fractional
shortening and ventricular dilation, changes not seen in
Angptl2Flox/Flox;aMHC-Cre mice (Supplementary Fig. 8f,g).
Moreover, increased expression of HF markers was attenuated
in Angptl2Flox/Flox;aMHC-Cre mice (Supplementary Fig. 8h),
suggesting that loss of cardiomyocyte-derived ANGPTL2 is
cardioprotective.
ANGPTL2 inactivates AKT-SERCA2a signalling in heart. To
identify mechanisms underlying the effect of ANGPTL2 on
cardiac contractility, we employed a pathway scan comparing
activation of signalling factors in hearts of Angptl2 KO and
WT control mice. That analysis showed that AKT and its
effectors mTOR and p70S6K were slightly activated, but not in a
statistically signiﬁcant manner, in the heart of Angptl2 KO mice
(Supplementary Fig. 6d). We then performed western blotting
analysis and observed activated AKT signalling and increased
SERCA2a protein levels in hearts of Angptl2 KO relative
to control mice (Fig. 6a–c). Conversely, AKT signalling was
attenuated and SERCA2a levels were signiﬁcantly decreased in
hearts of aMHC-Angptl2 Tg mice (Fig. 6a,b,d). Moreover,
AKT activation and higher SERCA2a protein levels were
observed in Angptl2-KD NRCMs relative to controls (Fig. 6e–g),
and increased SERCA2a levels induced by Angptl2-KD were
signiﬁcantly attenuated in Angptl2-KD NRCMs overexpressing a
dominant-negative form of AKT (dnAKT) (Fig. 6i), suggesting
that Angptl2-KD increases SERCA2a expression in an
AKT-dependent manner. Conversely, AKT signalling was
markedly inhibited and SERCA2a protein levels were comparably
decreased in NRCMs overexpressing ANGPTL2 (Fig. 6e,f,h).
Thus, activation of AKT-SERCA2a signalling following
ANGPTL2 loss likely increases cardiac contractility, while
ANGPTL2 overexpression promotes the opposite phenotype.
ANGPTL2 perturbs the AKT-SERCA2a pathway via Integrin b1.
Our in vitro analysis suggests that ANGPTL2 is secreted from
cardiomyocytes, an idea conﬁrmed by observation that its
secretion signiﬁcantly decreased in supernatants of NRCMs
treated with Angptl2 siRNA (Supplementary Fig. 7e). Moreover,
AKT-SERCA2a signalling was signiﬁcantly downregulated in
NRCMs treated with recombinant human ANGPTL2 protein
(Supplementary Fig. 7f), a phenomenon consistent with
results seen in heart of aMHC-Angptl2 Tg mice and in NRCMs
overexpressing ad-ANGPTL2 (Fig. 6a,b,d–f,h).
We previously reported that integrin receptors play critical
roles in transducing ANGPTL2 signals in several tissues, however
these analyses did not include cardiomyocytes17,21. To investigate
whether ANGPTL2 activity in cardiomyocytes requires integrin
receptors, we prepared three siRNAs designed to target integrin
b1 and tested their efﬁciency in NRCMs (Supplementary Fig. 7g).
On the basis of that analysis we chose two siRNAs to test whether
integrin KD would alter ANGPTL2 signalling in cardiomyocytes.
As expected, NRCMs transfected control siRNA showed
downregulated AKT-dependent SERCA2a protein levels in
response to transfection with adenovirus-expressing ANGPTL2.
By contrast we observed little or no effect of ANGPTL2 on
AKT-dependent SERCA2a protein levels in cells transfected with
either of the integrin b1 siRNAs (Supplementary Fig. 7h),
suggesting that integrin b1 is required for ANGPTL2 activity in
this context.
Prevention of ANGPTL2 upregulation blocks HF development.
To assess whether in vivo transfer of anti-ANGPTL2 reagents
could counteract pathological cardiac remodelling, we delivered
Angptl2 shRNA cassettes into mouse heart by intravenous
injection of recombinant adeno-associated virus serotype
6 (AAV6) vector harbouring Angptl2 shRNA, as it has been
shown that systemic delivery of recombinant AAV6 vectors
preferentially transduces cardiac muscle35. We generated two
constructs expressing mouse Angptl2 shRNAs (AAV6-shAngptl2-
A and -B), and intravenously injected 1 1010 vg and 3 1010 vg
per mouse of each separately into WT mice. Two weeks later,
ANGPTL2 expression in hearts of mice injected with AAV6-
shAngptl2-B signiﬁcantly decreased, whereas the AAV6-shAngptl2-
A construct had no effect (Fig. 7a). Heart tissues from mice injected
with AAV6-shAngptl2-B showed increased expression of PGC-1a
and PPARa (Fig. 7b) and increased activation of AKT-SERCA2a
signalling (Fig. 7c) relative to controls. Notably, we observed no
adverse effects in terms of body weight, heart weight or expression of
inﬂammatory markers in hearts of mice injected with AAV6-
shAngptl2-B (Supplementary Fig. 9a–c), suggesting minimal
cardiotoxicity.
Next, we asked whether intravenous injection of
AAV6-shAngptl2-B suppressed ANGPTL2 upregulation in vivo
in the TAC model, in which hypertrophy develops 2 weeks after
surgery. To do so, we divided mice showing TAC-induced
cardiac dysfunction at 2 weeks into three groups and conﬁrmed
that there was no difference in cardiac dysfunction, as evaluated
by ultrasonic echocardiographic analysis among three
groups (Fig. 7f,h; Supplementary Fig. 9d). We then intravenously
injected mice with 1 or 3 1010 vg per mouse of recombinant
AAV6-shAngptl2-B or an equivalent doses of Scramble
control virus and examined cardiac function by ultrasonic
echocardiography at various time points after injection
(Fig. 7d). Both AAV6-shAngptl2-B doses suppressed increases
in ANGPTL2 concentrations seen in the circulation of control
animals (Supplementary Fig. 9e) as well as ANGPTL2
upregulation in stressed heart under pressure overload (Fig. 7e).
Control mice showed left ventricular dilatation with
reduced fractional shortening, whereas mice receiving either
AAV6-shAngptl2-B dose showed attenuated cardiac dysfunction
and a block in dilatation of the left ventricle, although ventricular
wall thickness was comparable in all mice (Fig. 7f–i;
Supplementary Fig. 9f). Heart weight per body weight ratios
decreased in mice injected with either AAV6-shAngptl2-B dose
relative to controls (Fig. 7j). Expression of HF markers
signiﬁcantly increased in hearts of control mice, while hearts of
mice treated with either AAV6-shAngptl2-B dose did not show
ANP or Myh7 upregulation (Fig. 7k).
ANGPTL2 suppression in human iPS-derived cardiomyocytes.
Next we asked whether ANGPTL2 suppression activated
AKT-SERCA2a signalling and enhanced energy metabolism in
human cardiomyocytes differentiated from iPS cells derived from
human ﬁbroblasts (see ‘Methods’ section). That analysis revealed
that human cardiomyocytes transfected with ANGPTL2 siRNA
showed decreased ANGPTL2 production and secretion, activated
AKT-SERCA2a signalling and increased PGC-1a and PPARa
expression relative to Scrambled siRNA controls (Fig. 8a–c).
Upregulation of cardiac ANGPTL2 production in HF patients.
Finally, we asked whether ANGPTL2 functions in pathological
cardiac remodelling by evaluating ANGPTL2 protein levels in
heart tissues obtained at autopsy from patients diagnosed with
chronic HF (n¼ 3) versus individuals who died in circumstances
unrelated to heart disease (n¼ 5). Immunohistochemistry with an
anti-ANGPTL2 antibody revealed abundant ANGPTL2 protein
in heart tissues from all three CHF patients (Fig. 8d for
representative results from CHF cases 1 and 2). By contrast, all
ﬁve control individuals showed cardiac ANGPTL2 protein levels
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lower than those seen in CHF patients (Fig. 8d for representative
results from non-CHF cases 1 and 2). We next asked which cell
types expressed Angptl2 in heart. Immunohistochemistry with an
anti-ANGPTL2 antibody revealed abundant ANGPTL2 protein
in aMHC-positive cardiomyocytes and CD31-positive capillary
vessel endothelial cells but not in periostin-positive cardiac
ﬁbroblasts in tissues from all three CHF patients (Fig. 8e for
representative results from CHF case 3).
The coronary sinus (Cs) drains blood primarily from the left
ventricular chamber of the heart. Therefore, potential differences
in ANGPTL2 concentration between the Cs and aortic root (Ao)
would reﬂect ANGPTL2 secretion from heart tissues, including
cardiomyocytes in the left ventricular chamber. To determine
whether that type of expression pattern correlates with ventricular
contractile dysfunction in patients, we compared ANGPTL2
concentration in the Cs and Ao of 58 patients with
non-secondary and non-familial dilated cardiomyopathy
(DCM) and observed signiﬁcantly elevated (435% increase)
ANGPTL2 production in heart tissues of 23 (Supplementary
Table 1). However, we observed no difference in severity of
cardiac dysfunction between these 23 and the 35 patients that did
not exhibit this pattern, as determined by several clinical indices
(Supplementary Table 1). Patients with signs of increased
cardiac ANGPTL2 secretion were generally older and exhibited
mildly enlarged left ventricular end-diastolic dimension (LVDd)
diameter compared with other patients (Supplementary Table 1).
Discussion
The main ﬁndings of this study are: (1) cardiac ANGPTL2
production increases in stressed mouse heart as it undergoes
pathological remodelling and potentially in some DCM
patients; (2) pathological stimuli increase cardiomyocyte
ANGPTL2 production via calcineurin-NFAT signalling; (3)
ANGPTL2 protein secreted from cardiomyocytes predisposes
heart to HF development likely by perturbing left ventricular
contractile ability, an outcome attributable to inactivation of
AKT-SERCA2a signalling and decreased myocardial energy
metabolism in cardiomyocytes; (4) exercise training and/or
miR-221/222 activity decreases cardiac ANGPTL2 expression;
(5) Angptl2 KO mice are protected from pathological cardiac
remodelling, and their heart phenotypes resemble those induced
by exercise; (6) AAV6-shAngptl2 blocks cardiac ANGPTL2
upregulation in heart stressed by pressure overload and blocks
the transition to HF by activating AKT-SERCA2a signalling and
improving energy metabolism in cardiomyocytes in mice; and (7)
AKT-SERCA2a is activated and myocardial energy metabolism is
enhanced in ANGPTL2-KD human iPS-derived cardiomyocytes.
Overall, we showed that increased cardiac ANGPTL2 activity
accelerates cardiac dysfunction and that therapeutic ANGPTL2
suppression could antagonize this dysfunction.
Others reported that circulating ANGPTL2 levels in HF
patients were higher than in control individuals, and that
cardiac function was inversely correlated with levels of
ANGPTL2 circulating in the periphery36. The authors did not
address underlying mechanisms, but noted that increased levels
of circulating ANGPTL2 in these patients could be secondary
to increased ANGPTL2 secretion from adipose tissues under
pathological conditions of HF. Such an outcome is feasible given
induction of adipose tissue inﬂammation and subsequent insulin
resistance seen in HF conditions37,38 and the fact that circulating
ANGPTL2 levels are relatively high in subjects with adipose tissue
inﬂammation and/or insulin resistance17. However, our study
strongly suggests that pathological stimuli activate ANGPTL2
production in cardiomyocytes, and that heart-derived ANGPTL2
is the likely source of increased ANGPTL2 levels in circulation in
HF conditions. Conversely, suppression of cardiac ANGPTL2
production by treatment of AAV6-shAngptl2 decreased
ANGPTL2 levels in circulation (Supplementary Fig. 9e). On
the other hand, to date we and others have independently
reported that circulating ANGPTL2 levels increase in various
pathological conditions other than obesity accompanied by
adipose tissue inﬂammation, such as atherosclerotic vascular
disease and type 2 diabetes and that these levels are
associated with disease severity17,20,39–41. Because, some of
these conditions are risk factors for HF development, further
studies are needed to investigate whether circulating ANGPTL2
affects cardiac function.
Non-pro-inﬂammatory ANGPTL2 function in cardiomyocytes
reported in this study is noteworthy, as ANGPTL2 reportedly acts
primarily by promoting progression of chronic inﬂammation16.
However, we do not exclude the possibility that cardiomyocyte-
derived ANGPTL2 may have a pro-inﬂammatory effect
during pathological cardiac remodelling. Indeed, we have also
reported that ANGPTL2 induces pro-inﬂammatory phenotypes
in macrophages (Supplementary Fig. 10)18,42, suggesting that
cardiomyocyte-derived ANGPTL2 modulates activity of cells
other than cardiomyocytes, such as inﬁltrated macrophages, in a
paracrine manner. If so, activities in those cells could promote
heart tissue inﬂammation, worsening cardiac dysfunction43.
Interestingly, a recent paper demonstrated that cardiac
miR-222 expression increased after endurance exercise training,
an activity required for physiological cardiomyocyte growth
in adult hearts, and that miR-222 expression protected against
adverse cardiac remodelling44. miR-221 and miR-222 target
the identical RNA sequence, and miR-221/222 overexpression in
mice antagonized pressure overload-induced pathological
cardiac remodelling45. However, it has been reported that
pressure overload-induced cardiac miR-221 promotes HF
development46,47. Thus, the role of cardiac miR-221/222
remains controversial. Here, we found that expression of
both miR-221 and miR-222 markedly increased in pressure
overload-induced cardiac stress following TAC (Supplementary
Fig. 5b). Notably, we also found that cardiomyocyte-speciﬁc
miR-221/222 KO mice were predisposed to HF development
(Supplementary Fig. 5c–f), suggesting that miR-221/222 functions
in cardioprotection. Accordingly, miR-221/222 KO mice showed
signiﬁcantly increased ANGPTL2 protein levels in stressed
heart after TAC (Supplementary Fig. 5g), suggesting that
ANGPTL2 is a direct target of miR-221/222 (ref. 42) (Fig. 4b,c)
and that miR-221/222 promotes cardioprotection via ANGPTL2
suppression (Supplementary Fig. 5).
Myocardial hypoxia is a critical pathology in HF
development48,49. Here, we also found that chronic hypoxia
occurs in heart tissues of TAC animals (Supplementary Fig. 11).
A recent paper reported that amelioration of aging-related
capillary and blood supply deﬁcits is associated with
downregulated expression of vascular endothelial growth factor
(VEGF), a key angiogenic factor, and its receptor (VEGFR) in
heart50. That study also reported that cardiac VEGF and VEGFR
mRNA levels increase following exercise training, increasing
cardiac capillarization50. These ﬁndings indicate overall that
VEGF signalling is critical for cardioprotective heart tissue
remodelling through maintaining myocardial oxygen levels. Our
study shows decreased ANGPTL2 production in mouse heart
after endurance exercise training (Fig. 4a) and increased
ANGPTL2 production in hearts of aged mice (Supplementary
Fig. 12). Moreover, both anti-VEGF therapy51 and chronic
hypoxia23 increase ANGPTL2 expression in tumour tissue. Since
ANGPTL2, like VEGF, possesses pro-angiogenic activity22,23,
increased ANGPTL2 expression in stressed hearts might be
caused by hypoxia. However, our observations support the idea
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that increased ANGPTL2 in stressed hearts likely decreases
cardiac contractility by perturbing AKT-SERCA2a signalling
and myocardial energy metabolism rather than counteracting
hypoxia by increasing angiogenesis. Thus, we hypothesize
that cardiac ANGPTL2 production is partially regulated by
myocardial oxygen levels, potentially down-regulating ANGPTL2
in physiological exercise-induced cardiac remodelling and
up-regulating it in pathological myocardial hypoxia-associated
remodelling.
Recent studies indicate that exercise-trained mice are protected
from HF development11,12 and that activation of PI3K-AKT
signalling is necessary for exercise-induced cardioprotection28.
Furthermore, Tg mice overexpressing AKT in cardiomyocytes
show cardiac hypertrophy with enhanced left ventricular function
associated with increased SERCA2a expression52,53. We also
observed cardioprotection following AKT-SERCA2a activation in
Angptl2 KO mice, while ANGPTL2 upregulation antagonized
AKT activation. Our ﬁndings in cultured cardiomyocytes suggest
that AKT is destabilized in the presence of ANGPTL2
(unpublished observations), although further investigation of
this activity is required.
Interestingly, we observed ANGPTL2 production in heart of
B40% of DCM patients tested here, suggesting that cardiac
dysfunction may be worsened by ANGPTL2 activity and that
this subset of patients might be candidates for therapeutic
ANGPTL2 suppression. These ﬁndings also suggest that
mechanisms underlying DCM vary among individuals and that
personalized medicine approaches are required to treat
these diseases. Moreover, we were surprised to ﬁnd that left
ventricular dilatation in cases of DCM harbouring some
ANGPTL2-associated cardiac dysfunction was milder than that
seen in DCM cases lacking an association with ANGPTL2. We
also observed that DCM patients showing upregulated cardiac
ANGPTL2 production were generally older than other DCM
patients (Supplementary Table 1). These ﬁndings suggest that the
impact of ANGPTL2 on progression of DCM may be less than
that of other mechanisms, and that evaluating changes in cardiac
ANGPTL2 production in DCM pathology might be useful to
predict DCM progression, although further investigation is
required. Moreover, it remains important to determine whether
cardiac ANGPTL2 production contributes to cardiac dysfunction
in HF patients without DCM. Interestingly, we also found
that ANGPTL2 production in hearts of aged mice increased
(Supplementary Fig. 12). Recently, abundant expression of
ANGPTL2 was reported as a senescence-associated secretory
phenotype factor in senescent cells54. Because pathologies are well
documented in the aging heart, cardiac ANGPTL2 activation
might be associated with dysfunction associated with aging.
ANGPTL2 reportedly interacts with the intracellular domain of
the Ang II type1a (AT1A) receptor and promotes its recycling in
non-cardiomyocyte cells55. In addition, we also recently reported
down-regulation of ANGPTL2/Arap1 function in sepsis-induced
hypotension due to reduced AT1A receptor recycling in
vascular cells56. Ang II signalling through AT1A closely follows
the progress of cardiac pathology, whereas suppression of
ANGPTL2/Arap1 expression did not alter Ang II downstream
signalling in cardiomyocytes (Supplementary Fig. 13), suggesting
that ANGPTL2/Arap1 activity is not essential for AT1A
receptor recycling in cardiomyocytes and that other AT1A
receptor-associated proteins, such as ATRAP, might regulate
recycling in this cellular context57.
In summary, this is the ﬁrst study to report that increased
ANGPTL2 activity induced in pathologically stressed heart
accelerates cardiac dysfunction (Fig. 9). ANGPTL2 suppression
restored cardiac function and myocardial energy metabolism,
blocking pathological remodelling.
Methods
Animal studies. All experimental procedures were approved by the Kumamoto
University Ethics Review Committee for Animal Experimentation. All animals
were fed a normal diet (ND; CE-2, CLEA, Tokyo, Japan), bred in a mouse house
with automatically controlled lighting (12 h on, 12 h off), and maintained at a stable
temperature of 23 C. Genetically engineered mice used in the study were: Angptl2
KO mice (Angptl2 KO)17 on a C57BL/6NJcl background, Tg mice overexpressing
EGFP driven by the murine aMHC promoter (aMHC-EGFP) on a C57BL/6J
background, purchased from the Laboratory Animal Resource Bank, National
Institutes of Biomedical Innovation, Health and Nutrition (Osaka, Japan), and Tg
mice overexpressing Cre driven by the murine aMHC promoter (aMHC-Cre)58,
kindly provided by Prof. Kinya Otsu (King’s College London, United Kingdom), on
a C57BL/6N background. Angptl2 KO mice were maintained by heterozygous
breeders. Angptl2 KO (6-, 10- and 12-week-old), aMHC-EGFP (10-week-old), and
aMHC-Cre (10-week-old) male mice were used in this study.
Generation of aMHC-Angptl2 transgenic mice. cDNA encoding mouse Angptl2
was cloned into the murine aMHC promoter expression vector in Supplementary
Fig. 3a, kindly provided by Dr Jeffrey Robbins (Heart Institute of Cincinnati
Children’s Hospital Medical Center)59. To identify Tg offspring, genomic PCR was
performed with forward (50-ACTTCTACATGAGATCATTC-30) and reverse
(50-GGTATTCTCAGGCTTCACCAGGTA-30) primers. To maintain an isogenic
strain, mice were propagated as heterozygotes by breeding with WT C57BL/6NJcl
mice (CLEA). Animals from F2 or F3 generations were used in all studies.
Generation of miR-221/222 conditional KO mice. miR-221/222 conditional
KO mice (miR-221/222Flox/y(male) and miR-221/222Flox/Flox(female)) on a C57BL/
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Figure 9 | Proposed mechanism underlying ANGPTL2 activity in heart.
Pathologic stimuli increase cardiomyocyte ANGPTL2 expression through
Calcineurin-NFAT signalling. Cardiac ANGPTL2 activity causes pathological
remodeling by down-regulating AKT-SERCA2A signalling, promoting
cardiac dysfunction and decreasing cardiac energy metabolism via PGC-1a
and PPAR-a down-regulation. Such pathological remodeling facilitates the
transition to HF.
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6N background were provided by the German Research Center for Environmental
Health (GmbH; Neuherberg, Germany). To genotype offspring, genomic PCR of
tail DNA was performed with forward (50-GCTCTGTTTTCCTAAGTGATGG-30)
and reverse (50-CTGACAGGAAGTAAATCATCTTAGC-30) primers. To maintain
an isogenic strain, mice were propagated as heterozygotes by breeding with WT
C57BL/6NJcl mice (CLEA).
Generation of Angptl2 conditional KO mice. Angptl2 conditional KO mice
(Angptl2Flox/Flox) on a C57BL/6J background were generated by UNITECH (Chiba,
Japan) as a custom order. In brief, to generate an Angptl2Flox/Flox construct,
genomic fragments from an Angptl2 BAC clone (Roswell Park Cancer Institute)
were cloned into the FRT-neo-FRT-loxP-DTA targeting vector, such that Angptl2
Exon2 was ﬂanked by loxP sites (Supplementary Fig. 8a). The targeting construct
was linearized by SacII and electroporated into C57BL/6J embryonic stem cells.
Homologously recombined embryonic stem (ES) cell clones were identiﬁed by PCR
and Southern blot. Chimeras were generated by injecting positive ES cells into
Balb/c blastocysts and subsequently identiﬁed by coat colour. Chimeric male
founder mice were mated to C57BL/6J female mice to generate F1 heterozygotes
for the Angptl2Flox/Flox line. Heterozygotes were crossed with FLP mice to delete
the neomycin cassette ﬂanked by FRT sites. To genotype offspring, genomic PCR of
tail DNA was performed with forward (50-ACACATGGAACAGAGTTACA
GCTTC-30) and reverse (50-AACTTTTTCAGAGATTTAGCACAGG-30) primers
(Supplementary Fig. 8b).
Establishment of hypertrophy mouse models. Male mice approximately
10-weeks-old (body weight of 23–25 g) were subjected to pressure overload using
TAC surgery. In brief, mice were anaesthetized by intraperitoneal injection of
pentobarbital, and anesthesia effects were assessed by a lack of response to toe
pinching. Respiration was artiﬁcially controlled during surgery. The aortic arch was
accessed via a left thoracotomy, and the thoracic aorta at the arch was surgically
constricted using a 27-gauge needle to generate trans-stenotic pressure, as
described elsewhere49. Sham mice underwent the same procedure without aortic
banding.
Echocardiography for mice. Mice were preconditioned by chest hair removal
with a topical depilatory (FujiFilm VisualSonics, Toronto, Canada), anaesthetized
with 1.5–2.5% isoﬂurane administered via inhalation, and maintained in a supine
position on a dedicated animal handling platform with limbs attached for
electrocardiogram gating during imaging. Body temperature was kept constant by
feeding the signal of a rectal probe back to a heating pad, while heart and
respiratory rates were continuously monitored. Transthoracic echocardiography
was performed using a high frequency ultrasound system dedicated to small
animal imaging (VisualSonics Vevo 2100, FujiFilm VisualSonics, Toronto, Canada)
using a MS 400 linear array transducer (18–38 MHz). M-mode recording was
performed at the midventricular level. All images were analyzed using dedicated
software (Vevo 2100 version 1.4). LV wall thickness and internal cavity
diameters at diastole (LVID;d) and systole (LVID;s) were measured. Per cent LV
fractional shortening (%FS) was calculated from M-mode measurements.
All procedures were performed under double-blind conditions with regard to
genotype or treatment.
Angiotensin II treatment. Angiotensin II (Ang II, Peptide Institute, Osaka, Japan)
was dissolved in 150mM NaCl and 1mM acetic acid. Dorsal subcutaneous tissues
of mice (male, 10-week-old) were implanted with a mini-osmotic pump (Model
2004, Alzet Corp., Palo Alto, CA, USA) to infuse Ang II (3mg kg 1 per day)
continuously for 2 weeks. Vehicle-treated groups underwent the same procedure
with vehicle (150mM NaCl and 1mM acetic acid)-ﬁlled pumps.
Isolation of cardiomyocytes and non-cardiomyocytes. Ventricles (three
hearts per sample) were harvested from aMHC-EGFP transgenic mice (male,
10-week-old), and tissue was minced into small pieces and digested by 0.075%
collagenase, 0.12% trypsin and 0.02% DNase at 37 C for 40min. Cells were
collected, resuspended and then passed through a 100-mm mesh ﬁlter into 50-ml
centrifuge tubes. Cells were ﬁnally resuspended with 0.5ml FACS buffer
(phosphate-buffered saline (PBS)/0.1% BSA) and GFP-positive (cardiomyocyte)
and GFP-negative (non-cardiomyocyte) cells were isolated using a cell sorter
FACSAria II (Becton Dickinson, San Jose, CA, USA).
To conﬁrm that Angptl2 is speciﬁcally deleted in cardiomyocytes of
Angptl2Flox/Flox; aMHC-Cre mice, we isolated cardiomyocytes and non-
cardiomyocytes from heart tissue of Angptl2Flox/Flox; aMHC-Cre and
Angptl2Flox/Flox mice (male, 10-week-old), as reported previously60. Brieﬂy,
ventricles were harvested from these mice and digested in 0.15% collagenase, 0.12%
trypsin and 0.02% DNase I for 40min. After digestion, cardiomyocytes and
non-cardiomyocytes were separated by percoll density gradient centrifugation.
Histological analysis. Mouse heart tissue samples were ﬁxed in 4% paraf-
ormaldehyde for 24 h and embedded in parafﬁn. Blocks were cut into 4-mm-thick
sections, air-dried and deparafﬁnized. Sections were stained with hematoxylin and
eosin (H&E; Wako, Osaka, Japan) to evaluate morphology, or with wheat germ
agglutinin (WGA) to evaluate cardiomyocyte size or Masson’s Trichrome
(Muto Pure Chemicals, Tokyo, Japan) to evaluate cardiac ﬁbrosis. Quantiﬁcation of
cardiomyocyte size after Alexa Fluor 594-conjugated WGA (Life Technologies,
Carlsbad, CA, USA) and DAPI (40 ,6-diamidio-2-phenylindole, Life Technologies)
staining was performed. In each ventricle, 100 cardiomyocytes were measured using
BZ-H2A software (Keyence). Measurements were limited to cardiomyocytes cut
perpendicular to their long axis at the level of a centred round cardiomyocyte
nucleus. Quantiﬁcation of ﬁbrosis areas was undertaken by visualizing blue-stained
areas. The ﬁbrotic area was calculated using Image J software (National Institutes of
Health) as the summation of blue-stained areas divided by total ventricular area. For
cardiac hypoxia analysis, 3 or 6 weeks after TAC mice were sacriﬁced 1 hour after
intraperitoneal injection of 10mgml 1 hypoxyprobe-1 (pimonidazole; Cosmo
Bio, Tokyo, Japan) in saline, a dosage of 60mgkg 1. Heart tissues were harvested
and parafﬁn-embedded. Blocks were cut into 4-mm-thick sections, air-dried and
deparafﬁnized. For immunostaining of pimonidazole adducts, specimens were
incubated with FITC-conjugated IgG1 mouse monoclonal anti-hypoxyprobe-1
antibody (5mgml 1) at 4 C overnight. After washing with PBS, secondary antibody
reaction was performed using Histoﬁne mouse stain kit (Nichirei Biosciences Inc)
according to the manufacturers’ instruction. Peroxidase activity was visualized
by incubation with a 3,3-diaminobenzidine solution. Slides were mounted and
examined using a BIOREVO BZ-9000 microscope (Keyence, Osaka, Japan).
Real-time quantitative RT-PCR analysis. Total RNA was isolated using an RNeasy
Mini Kit (Qiagen, Valencia, CA, USA). DNase-treated RNA was reverse transcribed
using a PrimeScript RT reagent Kit (Takara Bio Inc, Shiga, Japan). Heart tissue was
homogenized using a Multi-beads shocker (Yasui Kikai, Osaka, Japan). Real-time
quantitative RT-PCR was performed using SYBER Premix Ex Taq II (Takara Bio Inc)
and a Thermal Cycler Dice Real-Time system (Takara Bio). Relative transcript
abundance was normalized to that of 18S rRNA levels in mouse, rat and human
samples. Primer sets used for RT-PCR are listed in Supplementary Tables 2–4.
Measurement of cell shortenings and Ca2þ transients. After enzymatic
isolation of ventricular cardiomyocytes, cell shortenings and Ca2þ transients in single
cardiomyocytes were measured as described61. Ca2þ transients were recorded in
cardiomyocytes loaded with 10mM Indo-1 AM (Dojindo, Kumamoto, Japan).
Brieﬂy, isolated cardiomyocytes were stimulated in an electrical ﬁeld at 1 Hz using a
two-platinum electrode insert connected to a bipolar stimulator (SEN-3301, Nihon
Kohden, Tokyo, Japan) on the stage of an inverted microscope (IX71, Olympus,
Tokyo, Japan) with a 20 water immersion objective lens (UApo N340, Olympus).
Cell shortenings and Indo-1 ﬂuorescent signals were recorded using a high-
performance Evolve EMCCD camera (Photometrics, Tucson, AZ, USA) and analyzed
by MetaMorph software (version 7.7.1.0; Molecular Devices, Sunnyvale, CA, USA).
SR Ca2þ content was estimated by rapid extracellular application of 10mM caffeine
as described61. Caffeine-induced Ca2þ transients were recorded in cardiomyocytes
loaded with 5mM Fura-2 AM (Dojindo). The Fura-2 ﬂuorescence ratio was
determined using a Lambda DG-4 Ultra High Speed Wavelength Switcher (Sutter
Instruments, Novato, CA, USA). The maximal amplitude of Ca2þ transients
following caffeine application served as an index of SR Ca2þ content and was
analyzed using MetaFluor software (Molecular Devices). Experiments were performed
in cells superfused with Tyrode solution supplemented with 2mgml 1 BSA.
Western blot analysis. Mouse heart tissue was homogenized in lysis buffer
(10mM Tris–HCl, 1% Triton X-100, 50mM NaCl, 30mM sodium pyrophosphate,
50mM NaF, 5mM EDTA, 0.1mM Na3VO4, plus a protease inhibitor cocktail
(Nacalai Tesque, Kyoto, Japan), pH 7.5) using a Multi-beads shocker (Yasui
Kikai, Osaka Japan). Total protein (20 mg) or serum (0.1 ml) was separated by
SDS–PAGE, and transferred to PVDF membranes. Membranes were incubated
with anti-PDK1 (#3062), anti-p-PDK1 (S241) (#3438S), anti-AKT (#9272S),
anti-p-AKT (s473), (#9271), anti-p-AKT (T308) (#4056), anti-mTOR (#2983),
anti-p-mTOR(s2448) (#5536), anti-p-mTOR(s2481) (#2974), anti-p70S6k (#9202),
anti-p-p70S6k(T389) (#9205S), anti-Erk (#9102S), anti-p-Erk(T204/y202)
(#9106S), anti-AMPK (#2532S), anti-p-AMPK (T172) (#2535), anti-p-PKC(pan)
(#9371s), anti-PKCa (#2056s; Cell Signaling Technology, Danvers, MA) or anti-
Serca2a (ab3625; Abcam, Cambridge, MA, USA) antibodies diluted at 1:1,000 at
4 C overnight. After washing with PBST, membranes were incubated with 1:2,000
diluted horseradish peroxidase (HRP)-conjugated sheep anti-rabbit IgG (GE
Healthcare Life Science, Piscataway, NJ, USA) antibodies at room temperature for
60min. For Angptl2 immunoblotting, membranes were incubated with 1:3,000
diluted biotinylated goat anti-Angptl2 antibody (BAF1444; R&D Systems,
Minneapolis, MN, USA) at 4 C overnight. After washing with PBST, membranes
were incubated with 1:6,000 diluted HRP-conjugated streptavidin (Thermo Fisher
Scientiﬁc Inc., Waltham, MA, USA) at room temperature for 60min. Internal
controls were 1:2,000 diluted mouse anti-Hsc70 (sc-7298; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and 1:2,000 diluted HRP-conjugated sheep
anti-mouse IgG (GE Healthcare Life Science) antibodies, which were used as
primary and secondary antibodies, respectively. Blots were incubated with ECL
Western Blotting Detection Reagent (GE Healthcare Life Science), visualized using
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a Luminescent Image Analyzer LAS-4000 system (Fujiﬁlm, Tokyo, Japan) and
quantiﬁed with Multi Gauge software (Fujiﬁlm). Hsc70 was used for normalization.
Uncropped scans of all immunoblots are shown in Supplementary Fig. 14.
Measurement of intracellular ATP. ATP levels in heart tissues were determined
using an ATP assay kit (Toyo Ink, Tokyo, Japan) according to the manufacturer’s
instructions. Brieﬂy, heart tissue pieces (100mg) were homogenized in 10ml
homogenate buffer (0.25M sucrose in 10mM HEPES-NaOH, pH 7.4) and
centrifuged at 1,000g at 4 C for 10min. Supernatants were diluted eightfold on ice
in homogenate buffer. Then, 100 ml of the mixture was added to 100 ml ATP
extraction solution and luminescence was measured in Luminometer model
TD-20/20 (Turner Designs, Promega, Japan).
ATP levels in NRCMs were determined using the same kit. Brieﬂy, 48 hrs after
cells were transduced, NRCMs (2 105 cells) were washed with PBS twice and
suspended in 100 ml of PBS. The cell suspension was inoculated into 96-well plates
followed by the addition of 100 ml of ATP assay solution. After shaking for 1min
and incubation for 10min at room temperature, luminescence was measured using
a ﬂuoroskan ascent microplate luminometer (Thermo Fisher Scientiﬁc Inc) and
analyzed using Ascent software Version 2.6.
NRCM culture. NRCMs were prepared as described previously62. In brief,
ventricles of 1- to 2- day-old neonatal Wistar rats (Kyudo, Saga, Japan) were
dissociated in 0.06% trypsin, 0.025% collagenase type II and 20 mgml 1 of DNase I
for 40min. Cardiomyocytes were separately prepared by a percoll density gradient
procedure. NRCMs were collected and seeded at 1 105 cells per cm2 on Collagen
(type I)-coated 24-well culture plates (Wako). Cells were grown in 199/DMEM
medium (Life Technologies) supplemented with 10% fetal calf serum and
antibiotics in a humidiﬁed atmosphere at 37 C with 5% CO2. After 24 h, media
was changed before treatment with various reagents or adenovirus infection unless
otherwise speciﬁed.
ANGPTL2-KD in NRCMs were established by transfection with Mission siRNA
Universal Negative Control (siControl; Sigma-Aldrich) or with three validated
Mission siRNAs targeting Angptl2 (siAngptl2-A: SASI_Rn01_00093802:
GGAUCUUACUCACUCAAGATT, siAngptl2-B: SASI_Rn01_00093800:
GAGAGUACAUUUACCUCAATT, siAngptl2-C: SASI_Rn01_00093799:
CCAGAAAGCGAGUACUAUATT, Sigma-Aldrich) using Lipofectamine
RNAiMAX reagent (Life Technologies) according to the manufacturer’s
instructions. At 48 h later, cells were treated with TRI Reagent (Cosmo Bio, Tokyo,
Japan) in preparation for real-time RT-PCR or harvested and lysed with lysis buffer
for immunoblot analyses.
For constitutively active NFAT overexpression in NRCMs, NRCMs were
electroporated with pcDNA3.1 as a negative control or constitutively active mouse
NFATc3 expression plasmid, kindly provided by Dr Takashi Minami (Institute of
Resource Development and Analysis, Kumamoto University, Japan), using Amaxa
rat cardiomyocyte-neonatal nucleofector Kit and Nucleofector Device (Lonza,
Anaheim, CA, USA) according to the manufacturer’s instructions. After
electroporation, cells were plated and cultured for 24 h.
Production of recombinant adenovirus-expressing Angptl2 (Ad-Angptl2) was
conducted with Takara Bio. In brief, mouse Angptl2 cDNA was cloned into the
SmiI site of the pAxCAwtit2 cosmid vector (Takara Bio), which was used to
transfect 293 cells. Recombinant adenoviruses expressing dominant-negative AKT
(Ad-dnAKT) and LacZ (Ad-LacZ) were kindly provided by Dr Takashi Kadowaki
(Department of Metabolic Diseases, The University of Tokyo, Japan)63. NRCMs
were infected with adenovirus vectors 1 hr after seeding at a multiplicity of
infection of 50. Culture medium was then replaced with new medium for 48 h.
For treatment with exogenous protein, NRCM cultures were incubated with
10mgml 1 recombinant human ANGPTL2 for 24 h (ref. 23).
For Ang II and Isoproterenol (Iso; Sigma-Aldrich) treatment, NRCMs were
stimulated with 100 nM Ang II or 100 nM Iso for 6 and 12 h. For cyclosporine A
(CsA; Wako) treatments, NRCMs were pretreated with 10 mM CsA for 30min
before treatment with Ang II and Iso. For xestospongin C (Xes C; R&D systems)
treatments, NRCMs were pretreated with 1 mM Xes C for 30min before treatment
with Ang II.
For NFAT immunocytochemistry staining, NRCMs were plated on collagen-
coated coverslips with or without 100 nM Ang II in serum-free medium. After 12 h,
cells were rinsed with PBS, ﬁxed with 4% paraformaldehyde in PBS for 5min and
permeabilized with 0.4% Triton X-100 for 15min. Nonspeciﬁc binding was
minimized by blocking with 3% normal goat serum in PBS. Cells were incubated with
anti-NFATC1 (sc-7294; Santa Cruz Biotechnology) or NFATC4 polyclonal antibodies
(ab62613; Abcam) at 1mgml 1, followed by incubation with Alexa Fluor
488-conjugated anti-rabbit antibodies (Life Technologies). Nuclei were counterstained
with 40 ,60-diamidino-2-phenylindole (DAPI, Life Technologies, 1:200). Images were
obtained using a ﬂuorescence microscope (model BZ-9000; Keyence).
RAW264.7 cell culture and recombinant ANGPTL2 treatment. Mouse
macrophage cell line RAW264.7 (TIB-71, American Type Culture Collection) was
cultured in RPMI-1640 (Wako) containing 10% FCS in 5% CO/95% air at 37 C.
RAW264.7 cells were maintained in RPMI-1640 containing 1% FCS for 12 h and
then incubated for additional 6 h with or without 5 mgml 1 recombinant
mouse ANGPTL2 protein prepared as described previously23. After incubation, for
real-time RT-PCR analyses, total RNA from the cells was isolated as described
above. TaqMan probes for Mcp-1, Tnf-a, Ifng and 18S rRNA were purchased from
Applied Biosystems. Real-time RT-PCR was performed using a Light Cycler 480
(Roche Diagnostics).
Endurance exercise training. Ten-week-old male C57BL/6NJcl mice (CLEA
Japan) were allowed to adapt to the treadmill chamber (Model MK-690S/4M,
Muromachi, Japan) for 30min with unlimited movement. Mice were then
subjected to warm-up treadmill running for 15min (at 5mmin 1 for 5min,
10mmin 1 for 5min and 15mmin 1 for 5min) before real endurance exercise
training began. Mice began treadmill running at a 20mmin 1 for 60min as an
acute endurance exercise. For chronic endurance exercise, mice repeatedly
performed a warm-up for 15min and subsequent treadmill running at 20mmin 1
for 60min 5 days a week for 3 weeks. Mice were sacriﬁced 3 h after the last running
exercise and heart tissue analyzed.
To assess endurance capacity, aMHC-Angptl2 Tg and WT littermate male mice
were adapted to the treadmill chamber for 30min with unlimited movement and
then subjected to warm-up running for 15min (at 5mmin 1 for 5min,
10mmin 1 for 5min and 15mmin 1 for 5min) before training began. Mice
then began treadmill running at 20mmin 1 for 60min as an acute exercise. As a
chronic endurance exercise, mice repeatedly performed the warm-up for 15min
and then performed treadmill running at 20mmin 1 for 60min 5 days a week for
3 weeks. Exhaustion was deﬁned as falling back onto the grid more than three
times in 10 s or resting on the electric grid for more than 15 s.
Luciferase reporter assays. To construct a reporter plasmid (FLuc-Angptl2-
30UTR), the 30UTR of mouse Angptl2 was ampliﬁed from genomic DNA by PCR
and then cloned into an XbaI site downstream of the ﬁreﬂy luciferase (FLuc) gene in
the pGL3-Promotor Vector (Promega). To delete the miR-221/222 binding site from
the Angptl2-30UTR, we designed the following primer set: 50-CATTTCTCATGT
TCTGTGTATATATAAAAGGGAGG-30 and 50-AGAACATGAGAAATGCTGA
GGTAACAGGGCAG-30 . Deletion of the miR-221/222 binding site in the
Angptl2-30UTR reporter (Fluc-Angptl2-3’UTR-D 221/222) was performed using a
PrimeSTAR mutagenesis basal kit (Takara Bio) according to the manufacturer’s
instructions miR-221, miR-222, miR-211, miR-204 or miR-135a overexpression
vectors were constructed by inserting sequences including the full-length mature
microRNA sequences into pBApo-CMV (Takara Bio). NRCMs were co-transfected
with pcDNA3.1 as a negative control or plasmids encoding microRNA plus the
phRL-TK vector (Promega), which encodes renilla luciferase (RLuc) and either the
FLuc-Angptl2-30UTR or FLuc-Angptl2-30UTR-D221/222 using Lipofectamine 3000
reagent (Life Technologies). Luciferase activity was determined using a Dual Glo
luciferase assay system (Promega) according to the manufacturer’s instructions.
Recombinant AAV treatment. Production and puriﬁcation of recombinant AAV6
vectors were conducted with Takara Bio. In brief, for shRNA synthesis,
single-stranded DNA oligos A and B harbouring mouse Angptl2-targeting siRNA
and complementary strands were designed as follows: A-top 50-CTAGAGAGAGT
ACATTTACCTCAATAGTGCTCCTGGTTGTTGAGGTAAATGTACTCTCT
TTTTTA-30 and A-bottom 50-CTAGTAAAAAAGAGAGTACATTTACCTCAAC
AACCAGGAGCACTATTGAGGTAAATGTACTCTCT-30 ; B-top 50-CTAGAGC
CAGAAAGCGAGTACTATATAGTGCTCCTGGTTGTATAGTACTCGCTTTC
TGGCTTTTTTA-30 and B-bottom 50-CTAGTAAAAAAGCCAGAAAGCGAG
TACTATACAACCAGGAGCACTATATAGTACTCGCTTTCTGGCT-30 ;
Scramble-top 50-CTAGAGTCTTAATCGCGTATAAGGCTAGTGCTCCTGG
TTGGCCTTATACGCGATTAAGACTTTTTTA-30 and Scramble -bottom
50-CTAGTAAAAAAGTCTTAATCGCGTATAAGGCCAACCAGGAGCAC
TAGCCTTATACGCGATTAAGACT-30 . Single-stranded oligos (shAngptl2-A,
shAngptl2-B and shScramble) were annealed and cloned into the pAAV-2U6
vector (Takara Bio). Recombinant AAV6 vectors were produced with an
AAVpro Helper Free System (Takara Bio), puriﬁed by cesium chloride density
gradient centrifugation and dialyzed against PBS. The genome copy number
was determined using an AAVpro Titration Kit (for Real-time PCR) Ver. 2
(Takara Bio).
For analysis of TAC animals, 10-week-old male C57BL/6NJcl mice (CLEA
Japan) were subjected to TAC surgery and 2 weeks later anesthetized with
2% isoﬂurane and intravenously injected with recombinant AAV6 vectors at
1 1010 vg or 3 1010 vg. Cardiac function was examined using echocardiography
before injection (at 2 weeks after operation) and at 2 and 5 weeks afterwards. After
echocardiography at 5 weeks, mice were sacriﬁced and heart tissues subjected to
histological, real-time RT-PCR and immunoblot analyses. In some experiments
(Fig. 7a–c), 10-week-old male C57BL/6NJcl mice were intravenously injected with
recombinant AAV6 vectors at 1 1010 vg or 3 1010 vg. Two weeks after
injection, mice were sacriﬁced and heart tissues subjected to real-time RT-PCR and
immunoblot analyses.
ANGPTL2-KD in human iPS-derived cardiomyocytes. Human iPS cell lines
253G4 or 836B3 served as pluripotent cells. Cardiomyocyte differentiation of both
cell lines was induced as reported64,65. Derived cardiomyocytes were transfected
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with Mission siRNA Universal Negative Control (Sigma-Aldrich) or human
ANGPTL2-targeting siRNA (s23854: GAGAGUUCAUUUACCUAAATT, Life
Technologies) with Lipofectamine RNAi MAX reagent (Life Technologies)
according to the manufacturer’s instructions. At 12 h after transfection, the
medium was changed and cells were incubated for an additional 48 h. ANGPTL2
concentration in conditioned medium from transfected cells was estimated with an
ANGPTL2 ELISA kit (IBL, Fujioka, Japan) according to the manufacturer’s
instructions. Cells were treated with TRI Reagent (Cosmo Bio) for real-time
RT-PCR analyses or harvested and lysed with RIPA (50mM Tris–HCl, 150mM
NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% Nonidet P-40, 1mM EDTA,
Protease inhibitor (Roche Diagnostics), pH 7.5) buffer for immunoblot analyses.
Human studies. A total of 58 consecutive patients with DCM (40 men and 18
women; mean age±s.e.m., 54.7±1.7 years, Supplementary Table 1) were enroled
in the study. Twenty-six were classiﬁed as New York Heart Association (NYHA)
class I, 27 were class II and 5 were class III. Individuals with an episode of acute HF
within the previous 3 months or with renal dysfunction (estimated glomerular
ﬁltration rate (eGFR) of o30mlmin 1 1.73m 2) were excluded from the study.
All subjects underwent coronary angiography to exclude coronary artery disease
and endomyocardial biopsy to exclude myocarditis or speciﬁc muscle disease.
DCM was deﬁned as the presence of both a LVEF of o50% (as revealed by
contrast left ventriculography) and a dilated LV cavity in the absence of coronary
artery stenosis of 450%, valvular heart disease, arterial hypertension and
secondary cardiac muscle disease attributable to any known systemic condition66.
No patients had histories of acute viral myocarditis or familial DCM. There was
also no evidence that immune triggers functioned in DCM development in any
patient. Patients were in stable condition before their referral to Nagoya University
Hospital for cardiac catheterization. Endomyocardial biopsy was performed to
exclude myocarditis or speciﬁc muscle disease. Written informed consent was
obtained from each patient before cardiac catheterization, and the study was
approved by the Human Ethics Committee of the Nagoya University School of
Medicine, Japan (protocol approval No. 359-7, Marc 16th/2015).
Cardiac catheterization analysis. All patients underwent diagnostic right and left
heart catheterization as previously described67. In brief, pulmonary arterial wedge
pressure and cardiac output (CO) were measured with the use of a Swan–Ganz
catheter inserted through the right internal jugular vein. Cardiac index (CI) was
calculated as follows: CI¼CO per body surface area (lmin 1m 2). Coronary
angiography and left ventriculography via the right radial or femoral artery were
also performed. A 6F ﬂuid-ﬁlled pigtail catheter was positioned in the left ventricle
for measurement of LV pressure. EF was assessed by left ventriculography using the
area-length method. To examine transcardiac release of serum ANGPTL2, at the
time of biventricular catheterization ANGPTL2 from the aortic root (Ao) and
ANGPTL2 from the coronary sinus (CS) were collected simultaneously. Serum
ANGPTL2 levels were determined with human ANGPTL2 ELISA kits (IBL).
Ultrasonic echocardiographic analysis of human patients. Two-dimensional
echocardiography was performed using a ViVid 7 system (ViVid 7, GE Healthcare,
Milwaukee, WI, USA) as described67. We measured LV end-diastolic dimension
(LVDd), LV end-systolic dimension (LVDs) and left arterial dimension (LAD).
Percent fractional shortening (%FS) was calculated from LVDd and LVDs. The LV
mass index (LVMI) was calculated from two-dimensional measurements according
to a formula approved by the American Society of Echocardiology68.
Immunohistological analysis. Human heart tissue samples were obtained from
autopsy cases, including from congestive HF (CHF) patients and non-CHF
patients. In all cases, written informed consent was obtained from relevant families.
The study was also approved by the Ethics Committees of Kumamoto University.
Human heart tissue samples were ﬁxed in 4% paraformaldehyde for 24 h and
embedded in parafﬁn. Blocks were cut into 4-mm-thick sections, air-dried and
deparafﬁnized. For immunohistochemistry, sections were pretreated with periodic
acid (Nichirei, Tokyo, Japan) to inhibit endogenous peroxidases. Subsequently,
specimens were incubated overnight with rabbit polyclonal anti-human ANGPTL2
antibody (1 mgml 1) produced by immunizing rabbits with a synthetic peptide
corresponding to amino acids 383–400 (SFRLEPESEYYKLRLGRY) of human
ANGPTL2 at 4 C (ref. 23). After washing with PBS, specimens were incubated
with 500-fold diluted goat anti-rabbit IgG conjugated with peroxidase (GE
Healthcare Life Science) as second antibody at room temperature for 60min, and
specimens were then counterstained with hematoxylin. As negative controls, the
same procedures were performed using isotype control IgG in place of the primary
antibodies. Peroxidase activity was visualized by incubation with a 3,3-
diaminobenzidine solution and analyzed by light microscopy (model BZ-9000;
Keyence). For double immunoﬂuorescent staining, a rabbit polyclonal anti-human
ANGPTL2 antibody (1 mgml 1) was used with goat polyclonal anti-human MYH6
(sc-168676; Santa Cruz Biotechnology, 1 mgml 1), mouse monoclonal anti-human
CD31 (JC70A; DKO, Glostrup, Denmark, 2 mgml 1) and goat polyclonal
anti-human PERIOSTIN (sc-49480; Santa Cruz Biotechnology, 2 mgml 1). Alexa
Fluor 488-conjugated anti-rabbit or Alexa Fluor 594-conjugated anti-goat/mouse
antibody (Life Technologies, 10 mgml 1) served as secondary antibody. After
washing with PBS, ﬂuorescent images were captured by confocal laser microscopy
(LSM410, Zeiss, Jena, Germany).
Statistical analysis. No statistical methods were used to determine sample size,
but the sample sizes were similar to those of previous reports49. No exclusion/
inclusion criteria were applied to the mice used in this study. Group allocation and
outcome assessment were performed in a blinded manner. In vitro experiments
were repeated at least three times. All values were reported as the mean±s.e.m.
Data were assessed with two-group comparisons of variables by unpaired two-
tailed t test, with multiple comparisons by one-way ANOVA or two-way ANOVA
with Tukey’s multiple comparisons test between each group. Mouse survival data
was analyzed by the Kaplan–Meier log-rank test. Analysis of Kaplan–Meier and
ANOVA data was performed using GraphPad Prism software (version 6.0,
GraphPad Software). A value of Po0.05 was considered statistically signiﬁcant.
Data availability. All data generated or analyzed during this study are included in
this published article and its Supplementary information ﬁles, or are available from
the corresponding author on reasonable request.
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